GlassScriptPhysician profile
Maurice G Sholas
NPI 1124040134
$11,621.53
in general payments reported to CMS, 2019-2025
11 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $49.87 · 2021: $2,152 · 2022: $4,446 · 2023: $4,146 · 2024: $429 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,890 · Travel and Lodging: $1,836 · Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,890.00 |
| Travel and Lodging | $1,836.30 |
| Food and Beverage | $972.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ns Pharma, INC. | $10,122.77 | 2021-2023 | Viltepso |
| Gilead Sciences, INC. | $396.04 | 2019-2024 | Biktarvy |
| Ipsen Biopharmaceuticals, INC | $259.43 | 2023-2024 | Dysport |
| Viiv Healthcare Company | $254.55 | 2023-2024 | |
| Ptc Therapeutics, INC. | $176.03 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2019 | |
| Merck Sharp & Dohme LLC | $83.60 | 2025 | |
| Pfizer INC. | $61.44 | 2019 | |
| Sarepta Therapeutics, INC. | $52.18 | 2022-2023 | Elevidys |
| Novo Nordisk INC | $49.87 | 2020 | |
| Itf Therapeutics LLC | $40.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Sholas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.